BNP PARIBAS ASSET MANAGEMENT Holding S.A. Increases Stake in Stryker Co. (NYSE:SYK)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Stryker Co. (NYSE:SYK - Free Report) by 4.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,506 shares of the medical technology company's stock after purchasing an additional 2,322 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.'s holdings in Stryker were worth $18,246,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. King Luther Capital Management Corp boosted its position in shares of Stryker by 0.3% during the 3rd quarter. King Luther Capital Management Corp now owns 393,826 shares of the medical technology company's stock valued at $142,274,000 after acquiring an additional 1,357 shares during the last quarter. Citizens Financial Group Inc. RI raised its stake in Stryker by 9.9% in the third quarter. Citizens Financial Group Inc. RI now owns 55,673 shares of the medical technology company's stock valued at $20,113,000 after purchasing an additional 5,033 shares in the last quarter. Payden & Rygel lifted its position in Stryker by 0.4% during the third quarter. Payden & Rygel now owns 51,700 shares of the medical technology company's stock valued at $18,677,000 after purchasing an additional 200 shares during the last quarter. Moran Wealth Management LLC grew its stake in Stryker by 0.4% in the 3rd quarter. Moran Wealth Management LLC now owns 9,047 shares of the medical technology company's stock worth $3,268,000 after buying an additional 34 shares in the last quarter. Finally, Moors & Cabot Inc. raised its position in shares of Stryker by 0.4% during the 3rd quarter. Moors & Cabot Inc. now owns 10,643 shares of the medical technology company's stock valued at $3,845,000 after buying an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 7,347 shares of the company's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company's stock, valued at $3,685,213.16. This represents a 42.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares of the company's stock, valued at approximately $3,219,495. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock worth $24,825,275 over the last three months. Company insiders own 5.90% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on SYK shares. Royal Bank of Canada upped their target price on shares of Stryker from $386.00 to $400.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Wolfe Research assumed coverage on Stryker in a report on Tuesday, September 10th. They issued an "outperform" rating and a $405.00 price objective for the company. Evercore ISI raised their price objective on Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Stifel Nicolaus cut their target price on Stryker from $375.00 to $365.00 and set a "buy" rating for the company in a research note on Wednesday, July 31st. Finally, Robert W. Baird lifted their price target on shares of Stryker from $378.00 to $405.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and a consensus price target of $393.65.

Stryker Stock Performance

Shares of SYK stock opened at $384.88 on Friday. The firm has a market capitalization of $146.72 billion, a price-to-earnings ratio of 41.25, a PEG ratio of 2.94 and a beta of 0.91. The stock has a fifty day moving average of $366.20 and a 200 day moving average of $349.36. Stryker Co. has a 52 week low of $285.79 and a 52 week high of $398.20. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analysts' expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company posted $2.46 EPS. As a group, research analysts expect that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.